Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)

Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multiple cancers including melanoma, lung cancer, urothelial carcinoma, renal cell carcinoma, head and neck cancer, c...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Carol C., Barnes, Penny, Bigras, Gilbert, Boerner, Scott, Butany, Jagdish, Calabrese, Fiorella, Couture, Christian, Deschenes, Jean, El-Zimaity, Hala, Fischer, Gabor, Fiset, Pierre O., Garratt, John, Geldenhuys, Laurette, Gilks, C. Blake, Ilie, Marius, Ionescu, Diana, Lim, Hyun J., Manning, Lisa, Mansoor, Adnan, Riddell, Robert, Ross, Catherine, Roy-Chowdhuri, Sinchita, Spatz, Alan, Swanson, Paul E., Tron, Victor A., Tsao, Ming-Sound, Wang, Hangjun, Xu, Zhaolin, Torlakovic, Emina E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Hot Topic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887625/
https://www.ncbi.nlm.nih.gov/pubmed/31584451
http://dx.doi.org/10.1097/PAI.0000000000000800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887625/
https://www.ncbi.nlm.nih.gov/pubmed/31584451
http://dx.doi.org/10.1097/PAI.0000000000000800

Ejemplares similares